BACKGROUND: Efficient protection of dopaminergic neurons against a subsequent 6-hydroxydopamine lesion by glial cell line-derived neurotrophic factor (GDNF) gene delivery has been demonstrated. By contrast, the neurorestorative effects of GDNF administered several weeks after the toxin have been less characterized. In particular, whether these were permanent or dependent on the continuous presence of GDNF remains elusive. METHODS: A tetracycline-inducible adeno-associated virus (AAV)-1 vector expressing human GDNF cDNA was administered unilaterally in the rat striatum 5 weeks after 6-hydroxydopamine. Rats were treated with doxycycline (dox) or untreated from the day of vector injection until sacrifice (4 or 14 weeks). A sub-group was dox-tr...
Previous studies have used recombinant adeno-associated viral (rAAV) vectors to deliver glial cell l...
AbstractSeveral lines of evidence indicate that Glial cell line-derived neurotrophic factor (GDNF) i...
Rats with experimental Parkinson’s disease (PD) are treated with intravenous glial-derived neurotrop...
BACKGROUND: Efficient protection of dopaminergic neurons against a subsequent 6-hydroxydopamine lesi...
Gene transfer to the brain is a promising therapeutic strategy for a variety of neurodegenerative di...
Here we studied the effects of glial cell line-derived neurotrophic factor (GDNF) in a rat model tha...
Parkinson's disease (PD) is characterized by the progressive degeneration of the nigrostriatal dopam...
Glial cell-line derived neurotrophic factor (GDNF) is a good candidate agent for restoring functiona...
Parkinson's disease is characterized by a progressive degeneration of dopaminergic neurons in the su...
Previous studies have used recombinant adeno-associated vi-ral (rAAV) vectors to deliver glial cell ...
The effects of sustained (up to 9 months) striatal overexpression of glial cell line derived neurotr...
Current gene therapy models for Parkinson's disease (PD) have adapted two treatment strategies....
Sustained neurotrophic factor treatment in neurodegenerative disorders such as Parkinson's disease i...
The therapeutic potential of glial cell line-derived neurotrophic factor ( GDNF) for Parkinson's dis...
Parkinson's disease (PD) is a progressive and age-associated neurodegenerative disorder. Patients at...
Previous studies have used recombinant adeno-associated viral (rAAV) vectors to deliver glial cell l...
AbstractSeveral lines of evidence indicate that Glial cell line-derived neurotrophic factor (GDNF) i...
Rats with experimental Parkinson’s disease (PD) are treated with intravenous glial-derived neurotrop...
BACKGROUND: Efficient protection of dopaminergic neurons against a subsequent 6-hydroxydopamine lesi...
Gene transfer to the brain is a promising therapeutic strategy for a variety of neurodegenerative di...
Here we studied the effects of glial cell line-derived neurotrophic factor (GDNF) in a rat model tha...
Parkinson's disease (PD) is characterized by the progressive degeneration of the nigrostriatal dopam...
Glial cell-line derived neurotrophic factor (GDNF) is a good candidate agent for restoring functiona...
Parkinson's disease is characterized by a progressive degeneration of dopaminergic neurons in the su...
Previous studies have used recombinant adeno-associated vi-ral (rAAV) vectors to deliver glial cell ...
The effects of sustained (up to 9 months) striatal overexpression of glial cell line derived neurotr...
Current gene therapy models for Parkinson's disease (PD) have adapted two treatment strategies....
Sustained neurotrophic factor treatment in neurodegenerative disorders such as Parkinson's disease i...
The therapeutic potential of glial cell line-derived neurotrophic factor ( GDNF) for Parkinson's dis...
Parkinson's disease (PD) is a progressive and age-associated neurodegenerative disorder. Patients at...
Previous studies have used recombinant adeno-associated viral (rAAV) vectors to deliver glial cell l...
AbstractSeveral lines of evidence indicate that Glial cell line-derived neurotrophic factor (GDNF) i...
Rats with experimental Parkinson’s disease (PD) are treated with intravenous glial-derived neurotrop...